Deprescribing Overactive Bladder Medications in Parkinson's Disease
This study is looking at how gradually reducing (deprescribing) your overactive bladder (OAB) antimuscarinic medication affects people with Parkinson's disease (PD). Researchers want to see if this change impacts your thinking ability (cognitive function), other body functions (autonomic symptoms), and overall quality of life. You may be able to join if you are 60 or older, have Parkinson's disease, and have been taking an antimuscarinic for OAB for at least three months. The study will measure these effects over a period of up to 46 weeks. The current status of this study is unclear, and it plans to enroll 20 participants.
- Study design
- This is an unblinded, non-randomized study involving 20 participants with Parkinson's disease. It uses a crossover design where you will alternate between taking your medication and gradually reducing it.
- What's involved
- You will participate in periods of up to 10 weeks where you continue your medication, and periods where you gradually reduce it. Your cognitive function, autonomic symptoms, and quality of life will be assessed at the beginning and end of the study, up to 46 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your cognitive function, autonomic symptoms, and quality of life will be assessed at the completion of the study, up to 46 weeks from baseline.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Effects of deprescribing overactive bladder antimuscarinics on cognitive functionMoCA scores will be assessed at baseline (Visit 0) and at the completion of the study (Visit 41 or up to 46 weeks from baseline).
The investigators will evaluate the effects of deprescribing overactive bladder (OAB) antimuscarinics in individuals with Parkinson disease (PD) on their cognitive function, as measured by the change in participant's cognitive function using the Montreal Cognitive Assessment (MoCA) when they are "ON" vs. "OFF" antimuscarinics. The MoCA score ranges from 0 to 30, with higher scores indicating better cognitive function and lower scores indicating greater cognitive impairment.
- Effects of deprescribing overactive bladder antimuscarinics on autonomic symptom burdenSCOPA-AUT scores will be assessed at baseline (Visit 0) and at the completion of the study (Visit 41 or up to 46 weeks after baseline).
The investigators will evaluate the effects of deprescribing overactive bladder (OAB) antimuscarinics in individuals with Parkinson disease (PD) on autonomic symptom burden, as measured by the change in participant's Scales for Outcomes in Parkinson's - autonomic (SCOPA-AUT) when they are "ON" vs. "OFF" antimuscarinics. SCOPA-AUT total score ranges from 0 to 69, with higher scores indicating greater autonomic symptom burden and worse autonomic dysfunction.
- Effects of deprescribing overactive bladder antimuscarinics on quality of lifeQOL will be assessed at will be made at baseline (visit 0) and at the completion of the study (Visit 41 or up to 46 weeks from baseline).
The investigators will evaluate the effects of deprescribing overactive bladder (OAB) antimuscarinics in individuals with Parkinson disease (PD) on participant's quality of life (QOL), as measured by the change in participant's global impression of change using participant's QOL questionnaires when they are "ON" vs. "OFF" antimuscarinics. The baseline and end-of-study QOL questionnaires include questions about participant's current overall QOL (0=very poor, 1=poor, 2=fair, 3=good, 4=very good), current bladder-related QOL (0=very poor, 1=poor, 2=fair, 3=good, 4=very good), and current overall well-being affected by side effects of antimuscarinics (0=extremely, 1=quite a bit, 2=moderately, 3=a little, 4=not at all, 5=not applicable). The end-of-study QOL questionnaire include a question about overall state of health since the start of the study (0=very much worse, 1=minimally worse, 2=no change, 3=minimally improved, 4=very much improved). Higher scores indicate better QOL.